Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis (Q39574817)

13 September 2017

Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis (English)

1 reference

13 September 2017

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Elisa Sicuri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Timothy B Hallett

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mark Thursz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Lesong Conteh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Yusuke Shimakawa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Penda Suso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Saydiba Tamba

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ramou Njie

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Harr Njai

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Maud Lemoine

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

1 August 2016

1 reference

13 September 2017

The Lancet Global Health

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

e568-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27443782%20AND%20SRC:MED&resulttype=core&format=json

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Patterns of uptake of HIV testing in sub-Saharan Africa in the pre-treatment era.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980-2010).

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of hepatitis B virus infection in children.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of chronic hepatitis B REVEALed

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

The Natural Course of Hepatitis B Surface Antigen—Positive Chronic Active Hepatitis in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural course of patients with chronic type B hepatitis following acute hepatitis delta virus superinfection.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

The prognostic significance of bridging hepatic necrosis in chronic type B hepatitis: a histopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Thresholds for the cost-effectiveness of interventions: alternative approaches

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs.

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021

Requirements for global elimination of hepatitis B: a modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2816%2930101-2

7 January 2021